JND3229
- CAS No.
- 2260886-64-2
- Chemical Name:
- JND3229
- Synonyms
- JND3229;JND3229 (JND-3229;JND3229, 10 mM in DMSO;JND3229;JND-3229;JND 3229;N-(trans-4-(3-(2-Chlorophenyl)-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidin-1(2H)-yl)cyclohexyl)propionamide;N-[(1r,4r)-4-[3-(2-chlorophenyl)-7-{[3-methyl-4-(4-methylpiperazin-1-yl)phenyl]amino}-2-oxo-1H,2H,3H,4H-[1,3]diazino[4,5-d]pyrimidin-1-yl]cyclohexyl]propanamide;Propanamide, N-[trans-4-[3-(2-chlorophenyl)-3,4-dihydro-7-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl]cyclohexyl]-
- CBNumber:
- CB24844930
- Molecular Formula:
- C33H41ClN8O2
- Molecular Weight:
- 617.19
- MDL Number:
- MFCD32644591
- MOL File:
- 2260886-64-2.mol
- MSDS File:
- SDS
- TDS File:
- TDS
JND3229 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | KQD88664 | JND3229 | 2260886-64-2 | 25mg | $1396.5 | 2026-06-04 | Buy |
| Biosynth | KQD88664 | JND3229 | 2260886-64-2 | 50mg | $1943 | 2026-06-04 | Buy |
| Biosynth | KQD88664 | JND3229 | 2260886-64-2 | 100mg | $3110 | 2026-06-04 | Buy |
| ChemScene | CS-0078820 | JND3229 99.38% | 2260886-64-2 | 5mg | $173 | 2026-06-04 | Buy |
| ChemScene | CS-0078820 | JND3229 99.38% | 2260886-64-2 | 10mg | $271 | 2026-06-04 | Buy |
JND3229 Chemical Properties, Uses, Production
Uses
JND3229 is a reversible EGFRC797S inhibitor with IC50 values of 5.8, 6.8 and 30.5 nM for EGFRL858R/T790M/C797S, EGFRWT and EGFRL858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma[1].
in vivo
JND3229 (10 mg/kg; i.p.; twice daily for 10 days) exhibits an obvious suppression of tumor growth, and shows target inhibition in vivo[1].
| Animal Model: | BALB/c mice (bearing established BaF3-EGFR19D/T790M/C797S mouse xenograft tumors model)[1]. |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; twice daily for 10 days. |
| Result: | Caused an obvious suppression of tumor growth with a Tumor Growth Inhibition (TGI) value of 42.2%. Showed well tolerance without obvious body weight loss or other obvious toxic sign in the treated animals. Significantly decreased the level of phosphorylated EGFR (p-EGFR) tin the tumor tissues. |
References
[1] Lu X, et al. Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Med Chem Lett. 2018 Oct 8;9(11):1123-1127. DOI:10.1021/acsmedchemlett.8b00373
JND3229 Preparation Products And Raw materials
Raw materials
Preparation Products
JND3229 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Wuhan Kaymke Chemical Co., Ltd., | 027-87342388 18086026008 | sales@kaymke.com | China | 3537 | 55 |
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4859 | 55 | |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Shanghai Rechem science Co., Ltd. | 021-31433387 15618786686 | sales@rechemscience.com | China | 2969 | 58 |
| Shanghai Chaolan Chemical Technology Center | QQ：65489617 13301690235 | Sales@ATKchemical.com | China | 9729 | 58 |
| Chuzhou KeMail Chemical Technology Co., Ltd | 0550-5196001 15000891977 | wj520wjxby@126.com | China | 1940 | 55 |
| ROSEWA HOLDING GROUP CO.,LIMITED | +86-023-62871537 | sales@rosewachem.com | China | 2812 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 | sales@sarms4muscle.com | China | 10378 | 58 |
